Gene editing techniques, including CRISPR, prime editing, and nucleases, allow scientists to tackle genetic diseases, cancer, ...

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Pancreas development in pigs resembles humans much more closely than does the established mouse model. An international team ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

The Product Shortage PLUS Endorsement was developed in consultation with Cell One Partners Inc., a world leader in helping cell and gene therapy companies advance and achieve growth objectives toward ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

A naturally occurring gene called Cyclin A2 (CCNA2), which turns off after birth in humans, can actually make new, functioning heart cells and help the heart repair itself from injury, including a ...

"We do really have to give President ... But if you want to use CRISPR for gene therapy, you must first get the scissors, as ...

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...

The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...